The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Mantle Cell Lymphoma MORE >>

Combination therapy with acalabrutinib plus bendamustine and rituxumab showed an overall response rate in excess of 90% of patients with treatment-naïve mantle cell lymphoma and an ORR of 85% in patients with relapsed/refractory disease in an ongoing open-label phase Ib study. The safety profile was consistent with expected safety profiles for acalabrutinib and BR, said Tycel Phillips, MD, who presented the data at the 2018 American Society of Hematology Annual Meeting.

Latest JournalAll Journals >>

Special Reports B-Cell Malignancies
Special Reports

The Targeted Oncology mantle cell lymphoma resource center serves as a hub for all clinical news and expert insights related to this rare subtype of non-Hodgkin lymphoma. Content found here includes video interviews with lymphoma experts and key opinion leaders in the field sharing their perspectives on existing mantle cell lymphoma treatment options and management approaches, including case studies that describe the clinical presentation and diagnostic criteria for patients with MCL.

This page also houses the most recent issue of Evolving Paradigms: Mantle Cell Lymphoma. This educational journal offers information regarding mantle cell lymphoma prognosis, staging, and risk, as well as current and emerging therapies for the disease.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.